Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation
Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an increase in the incidence of nonalcoholic fatty liver disease. Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alco...
Uloženo v:
| Vydáno v: | Gastroenterology (New York, N.Y. 1943) Ročník 152; číslo 5; s. 1090 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.04.2017
|
| Témata: | |
| ISSN: | 1528-0012, 1528-0012 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an increase in the incidence of nonalcoholic fatty liver disease. Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alcoholic liver disease (ALD). We compared data on disease prevalence in the population with data from liver transplantation waitlists to evaluate changes in the burden of liver disease in the United States.
We collected data on the prevalence of HCV from the 2010 and 2013-2014 cycles of the National Health and Nutrition Examination Survey. We also collected data from the HealthCore Integrated Research Database on patients with cirrhosis and chronic liver failure (CLF) from 2006 through 2014, and data on patients who received transplants from the United Network for Organ Sharing from 2003 through 2015. We determined percentages of new waitlist members and transplant recipients with HCV infection, stratified by indication for transplantation, modeling each calendar year as a continuous variable using the Spearman rank correlation, nonparametric test of trends, and linear regression models.
In an analysis of data from the National Health and Nutrition Examination Survey (2013-2014), we found that the proportion of patients with a positive HCV antibody who had a positive HCV RNA was 0.5 (95% confidence interval, 0.42-0.55); this value was significantly lower than in 2010 (0.64; 95% confidence interval, 0.59-0.73) (P = .03). Data from the HealthCore database revealed significant changes (P < .05 for all) over time in percentages of patients with compensated cirrhosis (decreases in percentages of patients with cirrhosis from HCV or ALD, but increase in percentages of patients with cirrhosis from nonalcoholic steatohepatitis [NASH]), CLF (decreases in percentages of patients with CLF from HCV or ALD, with an almost 3-fold increase in percentage of patients with CLF from NASH), and hepatocellular carcinoma (HCC) (decreases in percentages of patients with HCC from HCV or ALD and a small increase in HCC among persons with NASH). Data from the United Network for Organ Sharing revealed that among patients new to the liver transplant waitlist, or undergoing liver transplantation, for CLF, there was a significant decrease in the percentage with HCV infection and increases in percentages of patients with nonalcoholic fatty liver disease or ALD. Among patients new to the liver transplant waitlist or undergoing liver transplantation for HCC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change between 2003 and 2015.
In an analysis of 3 different databases (National Health and Nutrition Examination Survey, HealthCore, and United Network for Organ Sharing), we found the proportion of patients on the liver transplant waitlist or undergoing liver transplantation for chronic HCV infection to be decreasing and fewer patients to have cirrhosis or CLF. However, the percentages of patients on the waitlist or receiving liver transplants for NASH or ALD are increasing, despite different relative burdens of disease among the entire population of patients with cirrhosis. |
|---|---|
| AbstractList | Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an increase in the incidence of nonalcoholic fatty liver disease. Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alcoholic liver disease (ALD). We compared data on disease prevalence in the population with data from liver transplantation waitlists to evaluate changes in the burden of liver disease in the United States.BACKGROUND & AIMSConcurrent to development of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an increase in the incidence of nonalcoholic fatty liver disease. Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alcoholic liver disease (ALD). We compared data on disease prevalence in the population with data from liver transplantation waitlists to evaluate changes in the burden of liver disease in the United States.We collected data on the prevalence of HCV from the 2010 and 2013-2014 cycles of the National Health and Nutrition Examination Survey. We also collected data from the HealthCore Integrated Research Database on patients with cirrhosis and chronic liver failure (CLF) from 2006 through 2014, and data on patients who received transplants from the United Network for Organ Sharing from 2003 through 2015. We determined percentages of new waitlist members and transplant recipients with HCV infection, stratified by indication for transplantation, modeling each calendar year as a continuous variable using the Spearman rank correlation, nonparametric test of trends, and linear regression models.METHODSWe collected data on the prevalence of HCV from the 2010 and 2013-2014 cycles of the National Health and Nutrition Examination Survey. We also collected data from the HealthCore Integrated Research Database on patients with cirrhosis and chronic liver failure (CLF) from 2006 through 2014, and data on patients who received transplants from the United Network for Organ Sharing from 2003 through 2015. We determined percentages of new waitlist members and transplant recipients with HCV infection, stratified by indication for transplantation, modeling each calendar year as a continuous variable using the Spearman rank correlation, nonparametric test of trends, and linear regression models.In an analysis of data from the National Health and Nutrition Examination Survey (2013-2014), we found that the proportion of patients with a positive HCV antibody who had a positive HCV RNA was 0.5 (95% confidence interval, 0.42-0.55); this value was significantly lower than in 2010 (0.64; 95% confidence interval, 0.59-0.73) (P = .03). Data from the HealthCore database revealed significant changes (P < .05 for all) over time in percentages of patients with compensated cirrhosis (decreases in percentages of patients with cirrhosis from HCV or ALD, but increase in percentages of patients with cirrhosis from nonalcoholic steatohepatitis [NASH]), CLF (decreases in percentages of patients with CLF from HCV or ALD, with an almost 3-fold increase in percentage of patients with CLF from NASH), and hepatocellular carcinoma (HCC) (decreases in percentages of patients with HCC from HCV or ALD and a small increase in HCC among persons with NASH). Data from the United Network for Organ Sharing revealed that among patients new to the liver transplant waitlist, or undergoing liver transplantation, for CLF, there was a significant decrease in the percentage with HCV infection and increases in percentages of patients with nonalcoholic fatty liver disease or ALD. Among patients new to the liver transplant waitlist or undergoing liver transplantation for HCC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change between 2003 and 2015.RESULTSIn an analysis of data from the National Health and Nutrition Examination Survey (2013-2014), we found that the proportion of patients with a positive HCV antibody who had a positive HCV RNA was 0.5 (95% confidence interval, 0.42-0.55); this value was significantly lower than in 2010 (0.64; 95% confidence interval, 0.59-0.73) (P = .03). Data from the HealthCore database revealed significant changes (P < .05 for all) over time in percentages of patients with compensated cirrhosis (decreases in percentages of patients with cirrhosis from HCV or ALD, but increase in percentages of patients with cirrhosis from nonalcoholic steatohepatitis [NASH]), CLF (decreases in percentages of patients with CLF from HCV or ALD, with an almost 3-fold increase in percentage of patients with CLF from NASH), and hepatocellular carcinoma (HCC) (decreases in percentages of patients with HCC from HCV or ALD and a small increase in HCC among persons with NASH). Data from the United Network for Organ Sharing revealed that among patients new to the liver transplant waitlist, or undergoing liver transplantation, for CLF, there was a significant decrease in the percentage with HCV infection and increases in percentages of patients with nonalcoholic fatty liver disease or ALD. Among patients new to the liver transplant waitlist or undergoing liver transplantation for HCC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change between 2003 and 2015.In an analysis of 3 different databases (National Health and Nutrition Examination Survey, HealthCore, and United Network for Organ Sharing), we found the proportion of patients on the liver transplant waitlist or undergoing liver transplantation for chronic HCV infection to be decreasing and fewer patients to have cirrhosis or CLF. However, the percentages of patients on the waitlist or receiving liver transplants for NASH or ALD are increasing, despite different relative burdens of disease among the entire population of patients with cirrhosis.CONCLUSIONSIn an analysis of 3 different databases (National Health and Nutrition Examination Survey, HealthCore, and United Network for Organ Sharing), we found the proportion of patients on the liver transplant waitlist or undergoing liver transplantation for chronic HCV infection to be decreasing and fewer patients to have cirrhosis or CLF. However, the percentages of patients on the waitlist or receiving liver transplants for NASH or ALD are increasing, despite different relative burdens of disease among the entire population of patients with cirrhosis. Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an increase in the incidence of nonalcoholic fatty liver disease. Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alcoholic liver disease (ALD). We compared data on disease prevalence in the population with data from liver transplantation waitlists to evaluate changes in the burden of liver disease in the United States. We collected data on the prevalence of HCV from the 2010 and 2013-2014 cycles of the National Health and Nutrition Examination Survey. We also collected data from the HealthCore Integrated Research Database on patients with cirrhosis and chronic liver failure (CLF) from 2006 through 2014, and data on patients who received transplants from the United Network for Organ Sharing from 2003 through 2015. We determined percentages of new waitlist members and transplant recipients with HCV infection, stratified by indication for transplantation, modeling each calendar year as a continuous variable using the Spearman rank correlation, nonparametric test of trends, and linear regression models. In an analysis of data from the National Health and Nutrition Examination Survey (2013-2014), we found that the proportion of patients with a positive HCV antibody who had a positive HCV RNA was 0.5 (95% confidence interval, 0.42-0.55); this value was significantly lower than in 2010 (0.64; 95% confidence interval, 0.59-0.73) (P = .03). Data from the HealthCore database revealed significant changes (P < .05 for all) over time in percentages of patients with compensated cirrhosis (decreases in percentages of patients with cirrhosis from HCV or ALD, but increase in percentages of patients with cirrhosis from nonalcoholic steatohepatitis [NASH]), CLF (decreases in percentages of patients with CLF from HCV or ALD, with an almost 3-fold increase in percentage of patients with CLF from NASH), and hepatocellular carcinoma (HCC) (decreases in percentages of patients with HCC from HCV or ALD and a small increase in HCC among persons with NASH). Data from the United Network for Organ Sharing revealed that among patients new to the liver transplant waitlist, or undergoing liver transplantation, for CLF, there was a significant decrease in the percentage with HCV infection and increases in percentages of patients with nonalcoholic fatty liver disease or ALD. Among patients new to the liver transplant waitlist or undergoing liver transplantation for HCC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change between 2003 and 2015. In an analysis of 3 different databases (National Health and Nutrition Examination Survey, HealthCore, and United Network for Organ Sharing), we found the proportion of patients on the liver transplant waitlist or undergoing liver transplantation for chronic HCV infection to be decreasing and fewer patients to have cirrhosis or CLF. However, the percentages of patients on the waitlist or receiving liver transplants for NASH or ALD are increasing, despite different relative burdens of disease among the entire population of patients with cirrhosis. |
| Author | Lalehzari, Mona Saeian, Kia Charlton, Michael Gorospe, Emmanuel C Goldberg, David Ditah, Ivo C Aronsohn, Andrew |
| Author_xml | – sequence: 1 givenname: David surname: Goldberg fullname: Goldberg, David email: david.goldberg@uphs.upenn.edu organization: Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Leonard Davis Institute of Health Economics, University of Pennsylvania Philadelphia, Pennsylvania. Electronic address: david.goldberg@uphs.upenn.edu – sequence: 2 givenname: Ivo C surname: Ditah fullname: Ditah, Ivo C organization: Division of Gastroenterology and Hepatology, Regions Hospital, St Paul, Minnesota – sequence: 3 givenname: Kia surname: Saeian fullname: Saeian, Kia organization: Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin – sequence: 4 givenname: Mona surname: Lalehzari fullname: Lalehzari, Mona organization: Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin – sequence: 5 givenname: Andrew surname: Aronsohn fullname: Aronsohn, Andrew organization: Division of Gastroenterology and Hepatology, University of Chicago Medical Center, Center for Liver Diseases, Chicago, Illinois – sequence: 6 givenname: Emmanuel C surname: Gorospe fullname: Gorospe, Emmanuel C organization: Prevea Center for Digestive Health, Green Bay, Wisconsin – sequence: 7 givenname: Michael surname: Charlton fullname: Charlton, Michael organization: Intermountain Medical Center, Murray, Utah |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28088461$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkdtO4zAQhq0VaDnsvsFqNZdc0GA7deJeVuEoVYAEu1xWE2fSGKV2sR0k3pGHIoiCuJpfmk_zf9IcsB3nHTH2R_BMcJWfPGYrjCn4THJRZlxknOc_2L5QUk84F3LnW95jBzE-cs5nuRY_2Z7UXOtpIfbZa9WhW1EE6yB1BLeBnrEnZwh8C5e0wWSTjVDBfxuGCFeuJZOsd8dw7R32xne-twbuEmHy3Sd_DOgamH-tF_aZApzaSBgJ5mvvVnA7ouRShAebOqhsCJ2PY5UPW_wcbT-EUeRD7QFt6m1M0H4R9wFd3PToEr47_WK7LfaRfm_nIft3fnZfXU4WNxdX1XwxMUoUadLmZaFqTlNet3mBrTCaGqUaURDVaEytsMy1bFAIaoqykQb1TGKTG9LlTBl5yI4-7m6CfxoopuXaRkP9KEJ-iEuhC6GmpeRyRP9u0aFeU7PcBLvG8LL8_IB8Aw9akQ8 |
| CitedBy_id | crossref_primary_10_23736_S1121_421X_20_02688_4 crossref_primary_10_1002_hep_29473 crossref_primary_10_1007_s12072_017_9807_0 crossref_primary_10_1097_MD_0000000000043395 crossref_primary_10_1111_ctr_14317 crossref_primary_10_1111_acer_13944 crossref_primary_10_1016_j_gastha_2022_12_001 crossref_primary_10_1016_S2468_1253_18_30339_X crossref_primary_10_3138_canlivj_2018_0010 crossref_primary_10_1186_s12910_023_00923_y crossref_primary_10_1002_cld_781 crossref_primary_10_1097_TP_0000000000002317 crossref_primary_10_3748_wjg_v24_i38_4403 crossref_primary_10_1097_TP_0000000000003404 crossref_primary_10_3748_wjg_v25_i13_1628 crossref_primary_10_1016_j_cgh_2017_11_045 crossref_primary_10_1016_j_cgh_2019_07_042 crossref_primary_10_1080_14787210_2019_1588112 crossref_primary_10_1089_jpm_2019_0100 crossref_primary_10_1002_cld_663 crossref_primary_10_1016_j_intimp_2025_115088 crossref_primary_10_1002_onco_13582 crossref_primary_10_1136_bmjopen_2020_039804 crossref_primary_10_1016_j_cgh_2020_11_042 crossref_primary_10_1177_17562848211062807 crossref_primary_10_1007_s11901_021_00569_7 crossref_primary_10_1016_j_suc_2021_09_005 crossref_primary_10_1016_j_transproceed_2019_07_021 crossref_primary_10_1007_s10620_019_05869_z crossref_primary_10_1097_TP_0000000000004865 crossref_primary_10_1016_j_jceh_2019_06_007 crossref_primary_10_1016_j_jceh_2020_02_003 crossref_primary_10_1159_000514953 crossref_primary_10_1111_apt_17547 crossref_primary_10_1111_liv_14248 crossref_primary_10_1186_s12967_019_02137_6 crossref_primary_10_1097_TXD_0000000000000800 crossref_primary_10_1097_MCG_0000000000001836 crossref_primary_10_1002_hep_31566 crossref_primary_10_1016_j_transproceed_2025_05_002 crossref_primary_10_1016_j_cld_2017_08_013 crossref_primary_10_1371_journal_pone_0301133 crossref_primary_10_3389_fpubh_2025_1467117 crossref_primary_10_1016_j_cgh_2019_07_060 crossref_primary_10_3389_frtra_2023_1223169 crossref_primary_10_3748_wjg_v29_i1_61 crossref_primary_10_1016_j_cld_2018_09_007 crossref_primary_10_1097_SLA_0000000000004071 crossref_primary_10_1016_j_cgh_2018_05_057 crossref_primary_10_1111_liv_14135 crossref_primary_10_3350_cmh_2020_0305 crossref_primary_10_2967_jnumed_125_270047 crossref_primary_10_1111_liv_14255 crossref_primary_10_1002_ueg2_12226 crossref_primary_10_2147_JHC_S344559 crossref_primary_10_1155_2018_1509851 crossref_primary_10_1002_hep_30125 crossref_primary_10_5582_bst_2017_01293 crossref_primary_10_1097_HEP_0000000000000914 crossref_primary_10_1016_j_jhep_2021_08_012 crossref_primary_10_1186_s12876_020_01585_5 crossref_primary_10_3389_fphar_2023_1082451 crossref_primary_10_3390_nu11122985 crossref_primary_10_1001_jamanetworkopen_2020_1997 crossref_primary_10_1016_j_cld_2020_08_008 crossref_primary_10_1038_s41598_025_95154_z crossref_primary_10_1186_s12902_020_00582_9 crossref_primary_10_1016_j_cld_2020_08_009 crossref_primary_10_1183_13993003_00546_2017 crossref_primary_10_1016_j_ejim_2020_02_001 crossref_primary_10_1097_TXD_0000000000000866 crossref_primary_10_1139_cjpp_2020_0259 crossref_primary_10_1002_hep_30254 crossref_primary_10_1016_j_clinre_2018_03_014 crossref_primary_10_3390_livers5030034 crossref_primary_10_3390_livers5030036 crossref_primary_10_1080_17474124_2019_1551132 crossref_primary_10_1111_apt_17833 crossref_primary_10_1016_j_eimce_2018_03_006 crossref_primary_10_1002_lt_26074 crossref_primary_10_1155_2020_4020249 crossref_primary_10_1177_21501319241247974 crossref_primary_10_1002_hep_32203 crossref_primary_10_1155_2022_3200932 crossref_primary_10_1007_s00228_020_03058_w crossref_primary_10_1016_j_disamonth_2022_101330 crossref_primary_10_1242_dmm_048355 crossref_primary_10_1053_j_gastro_2018_06_031 crossref_primary_10_1097_TP_0000000000002484 crossref_primary_10_1111_liv_15255 crossref_primary_10_3390_metabo13010011 crossref_primary_10_1016_j_jlr_2023_100382 crossref_primary_10_1111_liv_14292 crossref_primary_10_1111_liv_15381 crossref_primary_10_1053_j_sult_2021_03_001 crossref_primary_10_1038_s41572_018_0014_7 crossref_primary_10_3389_fnut_2025_1473487 crossref_primary_10_1038_s41418_020_00668_w crossref_primary_10_1007_s12664_019_00991_2 crossref_primary_10_1097_TP_0000000000002497 crossref_primary_10_1155_2020_8829346 crossref_primary_10_1080_17425255_2018_1472236 crossref_primary_10_1177_15353702211009228 crossref_primary_10_1111_ctr_13514 crossref_primary_10_1111_jocs_17183 crossref_primary_10_1016_j_hermed_2023_100795 crossref_primary_10_1097_TP_0000000000004311 crossref_primary_10_2217_hep_2017_0013 crossref_primary_10_1111_liv_16113 crossref_primary_10_1186_s12876_024_03525_z crossref_primary_10_1007_s11901_021_00580_y crossref_primary_10_3748_wjg_v26_i28_4018 crossref_primary_10_3390_ijms20225613 crossref_primary_10_1007_s00428_023_03496_8 crossref_primary_10_1002_hep_30045 crossref_primary_10_1093_ibd_izz043 crossref_primary_10_1002_lt_25351 crossref_primary_10_1016_j_jhep_2018_03_014 crossref_primary_10_1055_s_0041_1725023 crossref_primary_10_1111_liv_14301 crossref_primary_10_1186_s12944_021_01518_5 crossref_primary_10_1053_j_gastro_2018_12_036 crossref_primary_10_1155_2018_4956079 crossref_primary_10_1002_lt_25466 crossref_primary_10_1111_apt_14411 crossref_primary_10_3390_nu15030526 crossref_primary_10_1097_TP_0000000000002816 crossref_primary_10_1111_eci_14082 crossref_primary_10_3390_ijms21144939 crossref_primary_10_3389_fphar_2021_742465 crossref_primary_10_1007_s11901_017_0376_4 crossref_primary_10_1111_apt_15738 crossref_primary_10_1055_s_0041_1731707 crossref_primary_10_1002_hep4_1599 crossref_primary_10_1016_j_transproceed_2020_01_015 crossref_primary_10_1111_jvh_13782 crossref_primary_10_1016_j_jnutbio_2023_109347 crossref_primary_10_1002_hep_31173 crossref_primary_10_1038_s41591_018_0104_9 crossref_primary_10_1007_s10620_019_05716_1 crossref_primary_10_1016_j_gtc_2019_09_004 crossref_primary_10_1016_j_gtc_2019_09_005 crossref_primary_10_1016_j_cgh_2023_03_032 crossref_primary_10_1016_j_jhep_2017_09_024 crossref_primary_10_1007_s11901_017_0343_0 crossref_primary_10_1007_s10620_018_5123_3 crossref_primary_10_1111_tri_13903 crossref_primary_10_1016_S2468_1253_21_00195_3 crossref_primary_10_1002_lt_25443 crossref_primary_10_1016_j_tips_2018_01_003 crossref_primary_10_1097_TXD_0000000000001060 crossref_primary_10_1016_j_jhep_2019_05_018 crossref_primary_10_3390_ijms222111589 crossref_primary_10_3389_fcell_2021_704704 crossref_primary_10_1097_MCG_0000000000001452 crossref_primary_10_1111_ctr_14924 crossref_primary_10_1111_liv_15867 crossref_primary_10_1016_j_transproceed_2022_10_055 crossref_primary_10_1515_hmbci_2019_0044 crossref_primary_10_1007_s10620_019_05576_9 crossref_primary_10_1111_apt_16969 crossref_primary_10_1016_j_liver_2025_100274 crossref_primary_10_1002_edm2_112 crossref_primary_10_1038_s41598_018_31708_8 crossref_primary_10_1016_j_jhep_2018_02_012 crossref_primary_10_1016_j_diabet_2020_07_010 crossref_primary_10_1016_j_bbrc_2022_01_059 crossref_primary_10_1096_fj_201700866R crossref_primary_10_1016_j_biopha_2021_111587 crossref_primary_10_1111_liv_15674 crossref_primary_10_1016_j_cgh_2023_11_013 crossref_primary_10_1080_14656566_2020_1744564 crossref_primary_10_1097_MCG_0000000000001739 crossref_primary_10_3390_biom12081079 crossref_primary_10_1097_TP_0000000000003825 crossref_primary_10_1016_j_clinre_2023_102168 crossref_primary_10_1016_S1470_2045_20_30224_2 crossref_primary_10_1097_MOT_0000000000000468 crossref_primary_10_3390_medicina61040768 crossref_primary_10_1007_s00270_019_02363_x crossref_primary_10_5500_wjt_v10_i9_256 crossref_primary_10_4093_dmj_2017_41_6_430 crossref_primary_10_1002_hep4_1394 crossref_primary_10_1097_HEP_0000000000000978 crossref_primary_10_1097_TP_0000000000003973 crossref_primary_10_1096_fj_202300621R crossref_primary_10_1016_S0985_0562_24_00006_2 crossref_primary_10_1007_s11605_020_04628_0 crossref_primary_10_1016_j_aohep_2021_100304 crossref_primary_10_1002_lt_25497 crossref_primary_10_1016_j_jhep_2020_11_014 crossref_primary_10_1111_prd_12427 crossref_primary_10_3390_cancers16081521 crossref_primary_10_1097_MEG_0000000000001270 crossref_primary_10_1097_SLA_0000000000004797 crossref_primary_10_1007_s12020_019_01982_1 crossref_primary_10_1002_lt_25003 crossref_primary_10_3390_v15010137 crossref_primary_10_1136_flgastro_2019_101304 crossref_primary_10_1097_TP_0000000000004953 crossref_primary_10_1016_j_cgh_2023_04_005 crossref_primary_10_1016_j_ijbiomac_2017_08_087 crossref_primary_10_4254_wjh_v10_i1_41 crossref_primary_10_3748_wjg_v26_i12_1273 crossref_primary_10_1002_lt_25361 crossref_primary_10_1002_lt_26209 crossref_primary_10_1002_lt_26329 crossref_primary_10_1016_j_dld_2024_09_007 crossref_primary_10_1016_j_transproceed_2019_01_190 crossref_primary_10_1007_s11901_018_0423_9 crossref_primary_10_1002_advs_201801585 crossref_primary_10_1053_j_gastro_2018_07_008 crossref_primary_10_1016_j_jhep_2019_04_011 crossref_primary_10_1007_s00535_024_02098_8 crossref_primary_10_1016_j_jhep_2020_03_031 crossref_primary_10_1007_s43440_019_00020_1 crossref_primary_10_1007_s12020_019_02155_w crossref_primary_10_15252_emmm_202216592 crossref_primary_10_3389_fphar_2023_1152042 crossref_primary_10_4274_jtgga_galenos_2021_2021_9_21 crossref_primary_10_3389_fendo_2020_592373 crossref_primary_10_1002_hep4_1644 crossref_primary_10_1038_s41598_024_69053_8 crossref_primary_10_1111_jvh_13130 crossref_primary_10_1007_s00261_024_04730_w crossref_primary_10_3138_canlivj_2021_0003 crossref_primary_10_3748_wjg_v27_i29_4818 crossref_primary_10_1016_j_trre_2018_04_001 crossref_primary_10_1016_j_apsb_2022_08_018 crossref_primary_10_3390_medicina58101459 crossref_primary_10_1016_j_diii_2019_10_007 crossref_primary_10_1097_MEG_0000000000002335 crossref_primary_10_1016_j_jhepr_2025_101525 crossref_primary_10_1159_000518407 crossref_primary_10_1002_lt_24769 crossref_primary_10_1111_jvh_13022 crossref_primary_10_1007_s11894_018_0626_9 crossref_primary_10_1007_s12072_021_10182_x crossref_primary_10_1016_j_dld_2022_08_033 crossref_primary_10_1371_journal_pone_0220612 crossref_primary_10_1016_j_bpg_2017_09_003 crossref_primary_10_1080_2162402X_2023_2184991 crossref_primary_10_1097_MEG_0000000000001590 crossref_primary_10_1097_XCS_0000000000000209 crossref_primary_10_1016_j_cld_2023_01_003 crossref_primary_10_1016_j_jhep_2018_12_009 crossref_primary_10_3350_cmh_2022_0336 crossref_primary_10_1055_a_2338_1144 crossref_primary_10_1038_s41395_018_0373_4 crossref_primary_10_1111_ajt_15559 crossref_primary_10_1016_j_dld_2019_09_017 crossref_primary_10_1097_TXD_0000000000001345 crossref_primary_10_1016_S0140_6736_18_30425_2 crossref_primary_10_1038_s41575_019_0169_z crossref_primary_10_3748_wjg_v26_i21_2740 crossref_primary_10_1111_dom_15632 crossref_primary_10_3748_wjg_v24_i18_1989 crossref_primary_10_1001_jamanetworkopen_2019_6412 crossref_primary_10_1007_s00535_017_1415_1 crossref_primary_10_1007_s10396_020_01058_y crossref_primary_10_1016_j_jlr_2022_100318 crossref_primary_10_1016_j_freeradbiomed_2019_05_029 crossref_primary_10_1002_lt_25672 crossref_primary_10_1111_hepr_13854 crossref_primary_10_1111_tid_13466 crossref_primary_10_3748_wjg_v24_i12_1353 crossref_primary_10_1186_s12906_023_04318_9 crossref_primary_10_1097_MOT_0000000000000864 crossref_primary_10_1097_MOT_0000000000000502 crossref_primary_10_1111_joim_13035 crossref_primary_10_1002_hep_29723 crossref_primary_10_1136_gutjnl_2021_324915 crossref_primary_10_3390_biomedicines13030632 crossref_primary_10_1002_hep_29721 crossref_primary_10_1002_hep4_1794 crossref_primary_10_2147_JMDH_S528289 crossref_primary_10_1002_lt_25413 crossref_primary_10_1002_hep_30822 crossref_primary_10_1002_hep4_1556 crossref_primary_10_1111_apt_17158 crossref_primary_10_3390_ijms23137280 crossref_primary_10_3748_wjg_v28_i34_5036 crossref_primary_10_1371_journal_pone_0239393 crossref_primary_10_1097_LVT_0000000000000182 crossref_primary_10_1128_IAI_00376_21 crossref_primary_10_1097_MOT_0000000000000732 crossref_primary_10_1111_liv_13755 crossref_primary_10_3390_medicina58020290 crossref_primary_10_1016_j_jcyt_2024_03_488 crossref_primary_10_3390_biomedicines10010197 crossref_primary_10_1016_j_dld_2019_08_022 crossref_primary_10_1002_lt_25644 crossref_primary_10_1038_s41575_020_00386_1 crossref_primary_10_1016_j_cld_2018_06_002 crossref_primary_10_1002_hsr2_805 crossref_primary_10_1016_j_plipres_2023_101238 crossref_primary_10_1111_jch_13938 crossref_primary_10_1111_liv_13649 crossref_primary_10_1016_S2468_1253_18_30419_9 crossref_primary_10_1007_s15034_019_1527_1 crossref_primary_10_1002_lt_25754 crossref_primary_10_1111_jvh_13005 crossref_primary_10_1186_s12876_024_03256_1 crossref_primary_10_1186_s12916_017_0966_6 crossref_primary_10_4254_wjh_v9_i36_1315 crossref_primary_10_1038_s41395_018_0088_6 crossref_primary_10_2147_DMSO_S304357 crossref_primary_10_1016_j_ejmech_2023_115614 crossref_primary_10_1002_mnfr_201900487 crossref_primary_10_1097_TP_0000000000004202 crossref_primary_10_1038_s41598_018_28854_4 crossref_primary_10_1002_cld_932 crossref_primary_10_1080_07853890_2023_2168042 crossref_primary_10_31146_1682_8658_ecg_170_10_18_25 crossref_primary_10_1007_s40261_019_00785_6 crossref_primary_10_1016_j_bjid_2021_101546 crossref_primary_10_1148_radiol_212808 crossref_primary_10_1007_s11739_022_02971_5 crossref_primary_10_1016_j_jhep_2022_04_002 crossref_primary_10_1186_s12879_020_4898_y crossref_primary_10_3389_fendo_2023_1073498 crossref_primary_10_3390_jcm10245826 crossref_primary_10_3390_ijtm5010007 crossref_primary_10_1097_SGA_0000000000000488 crossref_primary_10_1210_endocr_bqab249 crossref_primary_10_1155_2018_5498953 crossref_primary_10_3748_wjg_v23_i26_4669 crossref_primary_10_1038_s41575_018_0014_9 crossref_primary_10_3389_fnut_2021_718661 crossref_primary_10_1002_hep_29887 crossref_primary_10_1124_dmd_121_000413 crossref_primary_10_3390_ijms21218138 crossref_primary_10_3389_fnut_2024_1426749 crossref_primary_10_1002_hep_30866 crossref_primary_10_1002_hep_30864 crossref_primary_10_1177_0003134820942178 crossref_primary_10_1038_s41395_018_0049_0 crossref_primary_10_1016_j_cgh_2019_01_001 crossref_primary_10_1038_s41395_018_0365_4 crossref_primary_10_1186_s13104_024_06814_8 crossref_primary_10_1007_s12072_020_10023_3 crossref_primary_10_1111_liv_14092 crossref_primary_10_34172_aim_2024_04 crossref_primary_10_1007_s43032_023_01303_y crossref_primary_10_1016_j_jhep_2018_06_010 crossref_primary_10_1111_1751_2980_12871 crossref_primary_10_1016_j_jhep_2018_06_013 crossref_primary_10_1097_TP_0000000000003147 crossref_primary_10_1080_07853890_2023_2264850 crossref_primary_10_1002_cld_920 crossref_primary_10_1002_jhbp_715 crossref_primary_10_1155_2018_9430953 crossref_primary_10_3389_ti_2022_10443 crossref_primary_10_1002_cld_808 crossref_primary_10_1177_0003134820945223 crossref_primary_10_1002_hep_31857 crossref_primary_10_1016_j_cgh_2020_06_066 crossref_primary_10_3389_fendo_2024_1506953 crossref_primary_10_1097_MD_0000000000033981 crossref_primary_10_1007_s11901_018_0429_3 crossref_primary_10_3390_cells10112978 crossref_primary_10_1097_MEG_0000000000001967 crossref_primary_10_3748_wjg_v24_i14_1491 crossref_primary_10_1016_j_bpg_2017_04_006 crossref_primary_10_1186_s12876_022_02575_5 crossref_primary_10_1177_03000605211047074 crossref_primary_10_4103_jrms_jrms_830_23 crossref_primary_10_1007_s10620_021_07206_9 crossref_primary_10_3389_fmed_2024_1477820 crossref_primary_10_3390_ijms21061907 crossref_primary_10_3390_ijms24021324 crossref_primary_10_14309_ajg_0000000000001292 crossref_primary_10_1016_j_cgh_2021_12_044 crossref_primary_10_1016_j_cgh_2020_10_034 crossref_primary_10_1016_j_jhep_2018_07_001 crossref_primary_10_1016_j_hpb_2019_07_015 crossref_primary_10_3390_nu14020386 crossref_primary_10_1055_s_0042_1751081 crossref_primary_10_1016_j_dld_2021_09_009 crossref_primary_10_1016_S2468_1253_19_30181_5 crossref_primary_10_1002_lt_25934 crossref_primary_10_1016_j_livres_2023_11_006 crossref_primary_10_2147_IJGM_S317081 crossref_primary_10_1002_sim_9358 crossref_primary_10_1016_j_humpath_2019_09_015 crossref_primary_10_1055_a_1862_9088 crossref_primary_10_1111_tri_13873 crossref_primary_10_3390_biomedicines10061232 crossref_primary_10_3390_cells9051212 crossref_primary_10_1016_j_ejmech_2021_114061 crossref_primary_10_1016_j_hpb_2018_06_1797 crossref_primary_10_1002_cld_710 crossref_primary_10_1002_lt_24832 crossref_primary_10_1111_dom_16233 crossref_primary_10_1111_tri_13424 crossref_primary_10_3748_wjg_v24_i26_2785 crossref_primary_10_1002_cld_718 crossref_primary_10_1038_s41395_018_0242_1 crossref_primary_10_1002_lt_24839 crossref_primary_10_1007_s00535_018_1461_3 crossref_primary_10_1002_lt_24956 crossref_primary_10_1002_lt_25925 crossref_primary_10_1002_hep_31781 crossref_primary_10_1016_j_jhep_2018_07_020 crossref_primary_10_1016_S2468_1253_17_30142_5 crossref_primary_10_1136_gutjnl_2019_318841 crossref_primary_10_1097_TXD_0000000000001781 crossref_primary_10_1111_hepr_13425 crossref_primary_10_3390_cancers12102778 crossref_primary_10_1001_jamadermatol_2022_1609 crossref_primary_10_1002_hep4_1851 crossref_primary_10_1186_s12986_024_00830_y crossref_primary_10_1016_j_aohep_2020_03_007 crossref_primary_10_1111_ajt_17131 crossref_primary_10_1016_j_jceh_2023_04_005 crossref_primary_10_1016_j_metabol_2019_154001 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1053/j.gastro.2017.01.003 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1528-0012 |
| ExternalDocumentID | 28088461 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: K08 DK098272 |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 1B1 1CY 1P~ 1~5 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 AAEDT AAEDW AAFWJ AAIKJ AALRI AAQFI AAQOH AAQQT AAQXK AAXUO ABCQX ABDPE ABJNI ABLJU ABMAC ABOCM ABWVN ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AENEX AEVXI AFCTW AFFNX AFHKK AFJKZ AFRHN AFTJW AGCQF AGHFR AGQPQ AI. AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BELOY BR6 C5W CAG CGR COF CS3 CUY CVF DU5 EBS ECM EFJIC EFKBS EIF EJD F5P FD8 FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W J5H K-O KOM L7B M41 MO0 N4W N9A NPM NQ- O9- OC. OHT ON0 P2P PC. QTD R2- RIG ROL RPZ SEL SES SJN SSZ UDS UGJ UV1 VH1 WH7 X7M XH2 Y6R YQJ Z5R ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c516t-f3765b0e40bf36af1c8ed55d16eebaccb5a7382da11ed67d2ca892ad3ce8795c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 489 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000397297700036&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0012 |
| IngestDate | Sun Sep 28 00:34:36 EDT 2025 Mon Jul 21 06:02:46 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Obesity DAA Therapy Population Analysis US |
| Language | English |
| License | Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c516t-f3765b0e40bf36af1c8ed55d16eebaccb5a7382da11ed67d2ca892ad3ce8795c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://www.gastrojournal.org/article/S0016508517300148/pdf |
| PMID | 28088461 |
| PQID | 1861547202 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1861547202 pubmed_primary_28088461 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-04-01 |
| PublicationDateYYYYMMDD | 2017-04-01 |
| PublicationDate_xml | – month: 04 year: 2017 text: 2017-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Gastroenterology (New York, N.Y. 1943) |
| PublicationTitleAlternate | Gastroenterology |
| PublicationYear | 2017 |
| SSID | ssj0009381 |
| Score | 2.6667068 |
| Snippet | Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an increase in the incidence of... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1090 |
| SubjectTerms | Adolescent Adult Carcinoma, Hepatocellular - epidemiology End Stage Liver Disease - epidemiology Ethnicity - statistics & numerical data Female Hepacivirus Hepatitis C, Chronic - blood Hepatitis C, Chronic - epidemiology Humans Liver Cirrhosis - epidemiology Liver Diseases, Alcoholic - epidemiology Liver Neoplasms - epidemiology Liver Transplantation Male Middle Aged Non-alcoholic Fatty Liver Disease - epidemiology Prevalence RNA, Viral - blood United States - epidemiology Waiting Lists Young Adult |
| Title | Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28088461 https://www.proquest.com/docview/1861547202 |
| Volume | 152 |
| WOSCitedRecordID | wos000397297700036&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTtxAEG0RiCIuZGfJooqUIw7TXtsnNJpkBBKM5pCEuY3KvTCOkA224Sv5KKrcHjhFipSLL27LLVe5urrr1XtCfE2VtqPEuCDPXB7EGjFQUWwCh9pJZ5Nce5Kks2w2U4tFPh8O3NoBVrmOiX2gNrXmM_IjqWjtjTPaqx9f3wSsGsXV1UFC45nYiiiVYUhXtnhiC88j5flSmYWZIvG6dS6Jjv58u8S2a7j9T2Y9cWcvm_WXJLNfbKYv_3ear8TOkGbC2PvFa7FhqzfixflQSH8r7n1XQQtlBZQCAjM5Yd9_BLWDE8s4665sYQK_y-a2hdMBs1Udwoxz915Xt9TAcOCuXq3HHwJWBsaPt88Y9QHffREIxixsBHPP5NrCRdmtYFI2zapu6VV1MwyfYslYeaj91C5Y2oecEdzjCM_IfoW-bap6J35Nf_ycnASDsEOgE5l2gaOolhQjG48KF6XopFbWJImRqbUFal0kmEUqNCilNWlmQo0qD9FE2rI2ug7fi82qruyeAGco_0RXKGcN7WxRUcZZhLHLUNLefqT3xZe1nZb043A1BCtb37bLJ0vti11v7OW1Z_hYhoqCb5zKg394-oPYZh_yaJ6PYstR2LCfxHN9R5-9-dx7JF1n8_MHvjzxMg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+the+Prevalence+of+Hepatitis+C+Virus+Infection%2C+Nonalcoholic+Steatohepatitis%2C+and+Alcoholic+Liver+Disease+Among+Patients+With+Cirrhosis+or+Liver+Failure+on+the+Waitlist+for+Liver+Transplantation&rft.jtitle=Gastroenterology+%28New+York%2C+N.Y.+1943%29&rft.au=Goldberg%2C+David&rft.au=Ditah%2C+Ivo+C&rft.au=Saeian%2C+Kia&rft.au=Lalehzari%2C+Mona&rft.date=2017-04-01&rft.issn=1528-0012&rft.eissn=1528-0012&rft.volume=152&rft.issue=5&rft.spage=1090&rft_id=info:doi/10.1053%2Fj.gastro.2017.01.003&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0012&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0012&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0012&client=summon |